Europe Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Country: Trend Forecast and Growth Opportunity
Europe preventive vaccines market was valued at $18.02 billion in 2022 and will grow by 5.1% annually over 2022-2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for preventive vaccines such as COVID-19 vaccines, and the increasing healthcare expenditure.
Highlighted with 62 tables and 55 figures, this 142-page report “Europe Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Europe preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Country.
Based on Vaccine Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Live/Attenuated Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• Toxoid Vaccines
• Conjugate Vaccines
• mRNA Vaccines
• Recombinant Vector Vaccines
• Other Vaccines
Based on Disease, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Pneumococcal Disease
• Poliovirus
• Hepatitis
• Influenza
• Measles, Mumps, and Rubella (MMR)
• Varicella
• Human Papilloma Virus
• COVID-19
• Other Diseases
By Administration, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Intramuscular Route
• Subcutaneous Route
• Oral Route
• Intravenous Injection
• Other Administration Routes
By Patient, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Pediatric Vaccines
o Pneumococcal
o Measles, Mumps, and Rubella (MMR)
o Varicella
o Hepatitis
o Poliovirus
o Haemophilus Influenzae B (HIB)
o Other Diseases
• Adult Vaccines
o Influenza
o Cervical Cancer
o Hepatitis
o Zoster
o Other Diseases
Geographically, the following national/local markets are fully investigated:
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
For each key country, detailed analysis and annual revenue ($ mn) are available for 2022-2032. The breakdown of national markets by Vaccine Type, Disease, and Administration over the forecast years are also included.
The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
AstraZeneca plc
Bavarian Nordic A/S
China National Biotec Group Company Ltd.
CSL Ltd.
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co.
Moderna Inc.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
1 Introduction 8
1.1 Industry Definition and Research Scope 8
1.1.1 Industry Definition 8
1.1.2 Research Scope 9
1.2 Research Methodology 12
1.2.1 Overview of Market Research Methodology 12
1.2.2 Market Assumption 13
1.2.3 Secondary Data 13
1.2.4 Primary Data 13
1.2.5 Data Filtration and Model Design 14
1.2.6 Market Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 Market Overview and Dynamics 20
2.1 Market Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the Market 25
2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery 27
2.2 Major Growth Drivers 31
2.3 Market Restraints and Challenges 37
2.4 Emerging Opportunities and Market Trends 40
2.5 Porter’s Fiver Forces Analysis 44
3 Segmentation of Europe Market by Vaccine Type 48
3.1 Market Overview by Vaccine Type 48
3.2 Live/Attenuated Vaccines 50
3.3 Inactivated Vaccines 51
3.4 Subunit Vaccines 52
3.5 Toxoid Vaccines 53
3.6 Conjugate Vaccines 54
3.7 mRNA Vaccines 55
3.8 Recombinant Vector Vaccines 56
3.9 Other Vaccines 57
4 Segmentation of Europe Market by Disease 58
4.1 Market Overview by Disease 58
4.2 Pneumococcal Disease 60
4.3 Poliovirus 61
4.4 Hepatitis 62
4.5 Influenza 63
4.6 Measles, Mumps, and Rubella (MMR) 64
4.7 Varicella 65
4.8 Human Papilloma Virus 66
4.9 COVID-19 67
4.10 Other Diseases 68
5 Segmentation of Europe Market by Administration 69
5.1 Market Overview by Administration 69
5.2 Intramuscular Route 71
5.3 Subcutaneous Route 72
5.4 Oral Route 73
5.5 Intravenous Injection 74
5.6 Other Administration Routes 75
6 Segmentation of Europe Market by Patient 76
6.1 Market Overview by Patient 76
6.2 Pediatric Vaccines 78
6.3 Adult Vaccines 80
7 European Market 2022-2032 by Country 82
7.1 Overview of European Market 82
7.2 Germany 85
7.3 U.K. 88
7.4 France 91
7.5 Spain 94
7.6 Italy 97
7.7 Russia 100
7.8 Rest of European Market 103
8 Competitive Landscape 105
8.1 Overview of Key Vendors 105
8.2 New Product Launch, Partnership, Investment, and M&A 108
8.3 Company Profiles 109
AstraZeneca plc 109
Bavarian Nordic A/S 111
China National Biotec Group Company Ltd. 114
CSL Ltd. 116
Daiichi Sankyo Co. Ltd 118
Emergent BioSolutions Inc. 120
GlaxoSmithKline plc 122
Johnson & Johnson 126
Merck & Co. 128
Moderna Inc. 130
Novavax, Inc. 131
Pfizer Inc. 133
Sanofi SA 137
Takeda Pharmaceutical Co. Ltd. 140
RELATED REPORTS 142
List of Tables:
Table 1. Snapshot of Europe Preventive Vaccines Market in Balanced Perspective, 2022-2032 18
Table 2. World Economic Outlook, 2021-2031 23
Table 3. World Economic Outlook, 2021-2023 24
Table 4. Scenarios for Economic Impact of Ukraine Crisis 28
Table 5. World Health Spending by Region, $ bn, 2013-2020 36
Table 6. Main Product Trends and Market Opportunities in Europe Preventive Vaccines Market 40
Table 7. Europe Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 48
Table 8. Europe Preventive Vaccines Market by Disease, 2022-2032, $ mn 58
Table 9. Europe Preventive Vaccines Market by Administration, 2022-2032, $ mn 69
Table 10. Europe Preventive Vaccines Market by Patient, 2022-2032, $ mn 76
Table 11. Europe Preventive Vaccines Market: Pediatric Vaccines by Disease, 2022-2032, $ mn 79
Table 12. Europe Preventive Vaccines Market: Adult Vaccines by Disease, 2022-2032, $ mn 81
Table 13. Europe Preventive Vaccines Market by Country, 2022-2032, $ mn 84
Table 14. Germany Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 86
Table 15. Germany Preventive Vaccines Market by Disease, 2022-2032, $ mn 86
Table 16. Germany Preventive Vaccines Market by Administration, 2022-2032, $ mn 87
Table 17. U.K. Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 89
Table 18. U.K. Preventive Vaccines Market by Disease, 2022-2032, $ mn 89
Table 19. U.K. Preventive Vaccines Market by Administration, 2022-2032, $ mn 90
Table 20. France Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 92
Table 21. France Preventive Vaccines Market by Disease, 2022-2032, $ mn 92
Table 22. France Preventive Vaccines Market by Administration, 2022-2032, $ mn 93
Table 23. Spain Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 95
Table 24. Spain Preventive Vaccines Market by Disease, 2022-2032, $ mn 95
Table 25. Spain Preventive Vaccines Market by Administration, 2022-2032, $ mn 96
Table 26. Italy Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 98
Table 27. Italy Preventive Vaccines Market by Disease, 2022-2032, $ mn 98
Table 28. Italy Preventive Vaccines Market by Administration, 2022-2032, $ mn 99
Table 29. Russia Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 101
Table 30. Russia Preventive Vaccines Market by Disease, 2022-2032, $ mn 101
Table 31. Russia Preventive Vaccines Market by Administration, 2022-2032, $ mn 102
Table 32. Preventive Vaccines Market in Rest of Europe by Country, 2022-2032, $ mn 104
Table 33. AstraZeneca plc: Company Snapshot 109
Table 34. AstraZeneca plc: Business Segmentation 110
Table 35. AstraZeneca plc: Product Portfolio 110
Table 36. Bavarian Nordic A/S: Company Snapshot 111
Table 37. Bavarian Nordic A/S: Marketed Products and Pipeline, as of July 2020 112
Table 38. China National Biotec Group Company Ltd.: Company Snapshot 114
Table 39. CSL Ltd.: Company Snapshot 116
Table 40. Daiichi Sankyo Co. Ltd.: Company Snapshot 118
Table 41. Emergent BioSolutions Inc.: Company Snapshot 120
Table 42. GlaxoSmithKline: Company Snapshot 122
Table 43. GlaxoSmithKline: Business Segmentation 123
Table 44. GlaxoSmithKline: Product Portfolio 124
Table 45. GlaxoSmithKline: Revenue, 2018-2020, $ bn 125
Table 46. GlaxoSmithKline: Recent Developments 125
Table 47. Johnson & Johnson: Company Snapshot 126
Table 48. Johnson & Johnson: Business Segments 127
Table 49. Merck & Co., Inc.: Company Snapshot 128
Table 50. Merck & Co., Inc.: Business Segmentation 128
Table 51. Merck & Co., Inc.: Revenue, 2018-2020, $ bn 129
Table 52. Moderna Inc.: Company Snapshot 130
Table 53. Novavax, Inc.: Company Snapshot 131
Table 54. Pfizer Inc.: Company Snapshot 133
Table 55. Pfizer Inc.: Business Segmentation 134
Table 56. Pfizer Inc.: Product Portfolio 135
Table 57. Pfizer Inc.: Revenue, 2018-2020, $ bn 136
Table 58. Pfizer Inc.: Recent Developments 136
Table 59. Sanofi: Company Snapshot 137
Table 60. Sanofi: Business Segmentation 137
Table 61. Sanofi: Revenue, 2018-2020, $ bn 139
Table 62. Takeda Pharmaceutical Co. Ltd.: Company Snapshot 140List of Figures:
Figure 1. Research Method Flow Chart 12
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2022-2032 17
Figure 4. Europe Preventive Vaccines Market, 2022-2032, $ mn 20
Figure 5. Development Stages of Preventive Vaccines 21
Figure 6. Impact of COVID-19 on Business 25
Figure 7. Primary Drivers and Impact Factors of Europe Preventive Vaccines Market 31
Figure 8. Leading Causes of Death in the World, 2000 and 2019, million 34
Figure 9. Worldwide Geriatric Population (60 years and above) by Region, 2015 & 2030, million 35
Figure 10. World Population 65 and Over, % of Total Population, 1950-2060 35
Figure 11. Primary Restraints and Impact Factors of Europe Preventive Vaccines Market 37
Figure 12. Investment Opportunity Analysis 41
Figure 13. Porter’s Fiver Forces Analysis of Europe Preventive Vaccines Market 44
Figure 14. Breakdown of Europe Preventive Vaccines Market by Vaccine Type, 2022-2032, % of Revenue 49
Figure 15. Europe Addressable Market Cap in 2023-2032 by Vaccine Type, Value ($ mn) and Share (%) 49
Figure 16. Europe Preventive Vaccines Market by Vaccine Type: Live/Attenuated Vaccines, 2022-2032, $ mn 50
Figure 17. Europe Preventive Vaccines Market by Vaccine Type: Inactivated Vaccines, 2022-2032, $ mn 51
Figure 18. Europe Preventive Vaccines Market by Vaccine Type: Subunit Vaccines, 2022-2032, $ mn 52
Figure 19. Europe Preventive Vaccines Market by Vaccine Type: Toxoid Vaccines, 2022-2032, $ mn 53
Figure 20. Europe Preventive Vaccines Market by Vaccine Type: Conjugate Vaccines, 2022-2032, $ mn 54
Figure 21. Europe Preventive Vaccines Market by Vaccine Type: mRNA Vaccines, 2022-2032, $ mn 55
Figure 22. Europe Preventive Vaccines Market by Vaccine Type: Recombinant Vector Vaccines, 2022-2032, $ mn 56
Figure 23. Europe Preventive Vaccines Market by Vaccine Type: Other Vaccines, 2022-2032, $ mn 57
Figure 24. Breakdown of Europe Preventive Vaccines Market by Disease, 2022-2032, % of Sales Revenue 59
Figure 25. Europe Addressable Market Cap in 2023-2032 by Disease, Value ($ mn) and Share (%) 59
Figure 26. Europe Preventive Vaccines Market by Disease: Pneumococcal Disease, 2022-2032, $ mn 60
Figure 27. Europe Preventive Vaccines Market by Disease: Poliovirus, 2022-2032, $ mn 61
Figure 28. Europe Preventive Vaccines Market by Disease: Hepatitis, 2022-2032, $ mn 62
Figure 29. Europe Preventive Vaccines Market by Disease: Influenza, 2022-2032, $ mn 63
Figure 30. Europe Preventive Vaccines Market by Disease: Measles, Mumps, and Rubella (MMR), 2022-2032, $ mn 64
Figure 31. Europe Preventive Vaccines Market by Disease: Varicella, 2022-2032, $ mn 65
Figure 32. Europe Preventive Vaccines Market by Disease: Human Papilloma Virus, 2022-2032, $ mn 66
Figure 33. Europe Preventive Vaccines Market by Disease: COVID-19, 2022-2032, $ mn 67
Figure 34. Europe Preventive Vaccines Market by Disease: Other Diseases, 2022-2032, $ mn 68
Figure 35. Breakdown of Europe Preventive Vaccines Market by Administration, 2022-2032, % of Sales Revenue 70
Figure 36. Europe Addressable Market Cap in 2023-2032 by Administration, Value ($ mn) and Share (%) 70
Figure 37. Europe Preventive Vaccines Market by Administration: Intramuscular Route, 2022-2032, $ mn 71
Figure 38. Europe Preventive Vaccines Market by Administration: Subcutaneous Route, 2022-2032, $ mn 72
Figure 39. Europe Preventive Vaccines Market by Administration: Oral Route, 2022-2032, $ mn 73
Figure 40. Europe Preventive Vaccines Market by Administration: Intravenous Injection, 2022-2032, $ mn 74
Figure 41. Europe Preventive Vaccines Market by Administration: Other Administration Routes, 2022-2032, $ mn 75
Figure 42. Breakdown of Europe Preventive Vaccines Market by Patient, 2022-2032, % of Revenue 77
Figure 43. Europe Addressable Market Cap in 2023-2032 by Patient, Value ($ mn) and Share (%) 77
Figure 44. Europe Preventive Vaccines Market by Patient: Pediatric Vaccines, 2022-2032, $ mn 78
Figure 45. Europe Preventive Vaccines Market by Patient: Adult Vaccines, 2022-2032, $ mn 80
Figure 46. Breakdown of European Preventive Vaccines Market by Country, 2022 and 2032, % of Revenue 83
Figure 47. Contribution to Europe 2023-2032 Cumulative Market by Country, Value ($ mn) and Share (%) 84
Figure 48. Preventive Vaccines Market in Germany, 2022-2032, $ mn 85
Figure 49. Preventive Vaccines Market in U.K., 2022-2032, $ mn 88
Figure 50. Preventive Vaccines Market in France, 2022-2032, $ mn 91
Figure 51. Preventive Vaccines Market in Spain, 2022-2032, $ mn 94
Figure 52. Preventive Vaccines Market in Italy, 2022-2032, $ mn 97
Figure 53. Preventive Vaccines Market in Russia, 2022-2032, $ mn 100
Figure 54. Preventive Vaccines Market in Rest of Europe, 2022-2032, $ mn 103
Figure 55. Growth Stage of Europe Preventive Vaccines Industry over the Forecast Period 105
Methodology/Research Approach
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.Research Programs/Design
| Historical Data (2015-2019) |
|
|
| Influencing Factors |
|
|
| Market Forecast (2021-2026) |
|
|
Market Size Estimation
Top-down and bottom-up approaches are used to validate the global Voluntary Carbon Offset market size market and estimate the market size for Company, regions segments, product segments and Application (end users).
The market estimations in this report are based on the marketed sale price of Voluntary Carbon Offset (excluding any discounts provided by the player, distributor, wholesaler or traders). The percentage splits, market share, and breakdowns of the product segments are derived on the basis of weights assigned to each of the segments on the basis of their utilization rate and average sale price. The regional splits of the overall Voluntary Carbon Offset market and its sub-segments are based on the percentage adoption or utilization of the given product in the respective region or country.
Major Company in the market is identified through secondary research and their market revenues determined through primary and secondary research. Secondary research included the research of the annual and financial reports of the top Company; whereas, primary research included extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs and marketing executives. The percentage splits, market share, Growth Rate and breakdowns of the product markets are determined through using secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Market Intellix and presented in this report
The following figure shows an illustrative representation of the overall market size estimation process used for this study.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Data Source
Secondary Sources
Secondary sources include such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, etc. This research study involves the usage of widespread secondary sources, directories, databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), and TRADING ECONOMICS, and News Network, statista, Federal Reserve Economic Data, annual reports, BIS Statistics, ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and Hospitals study of the Voluntary Carbon Offset market. It was also used to obtain important information about the top companies, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product Company (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end use (product buyers), and related key executives from various key companies and organizations operating in the global market.
Primary research was conducted to identify segmentation Type, product price range, product Application, key Company, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
Key Executives Interviewed
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|